4 October 2010 - WADA 2011 Prohibited List now published

WADA 2011 Prohibited List now published Montreal (CAN) – 4 October 2010   Following its approval by the World Anti-Doping Agency's (WADA) Executive Committee on 18 September 2010, the 2011 List of Prohibited Substances and Methods is now available. This List will take effect on 1 January 2011.   The 2011 List offers a number of changes compared to the 2010 List. These changes reflect the latest scientific advances and broad consensus in the anti-doping community. They are founded on expanding anti-doping knowledge, evidence from the field, and constantly growing understanding of doping practices and trends.   Declaration of Use A noteworthy amendment is the removal of the obligation for athletes to file a Declaration of Use for specific substances that are not prohibited.   Declarations of Use, which must be distinguished from Therapeutic Use Exemptions (allowing the use of a prohibited substance), are required in 2010 for salbutamol and salmeterol by inhalation; glucocorticosteroids administered by intra-articular, periarticular, peritendinous, epidural, intradermal and inhalation routes; as well as platelet-derived preparations that are not administered by intramuscular route.   Failure by an athlete to file a Declaration of Use does not result in 2010 in an allegation of an anti-doping rule violation. This administrative requirement was therefore removed for 2011.   Non-Approved Substances A new section – "Non-Approved Substances" – has been added. This "open" section addresses the issue of the abuse of pharmacological substances for the purpose of performance enhancement that are not included in other sections of the List and that are not approved by any governmental regulatory health authority for human therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued). These substances will be prohibited at all times (in- and out-of-competition) in 2011.   Platelet-Derived Preparations Platelet-derived preparations (commonly referred as PRP or blood spinning), prohibited in 2010 when used by intra-muscular route, have been removed from the List for 2011 after consideration of the lack of current evidence concerning the use of these methods for purposes of performance enhancement. Current studies on platelet-derived preparations do not demonstrate potential for performance enhancement beyond a potential therapeutic effect. WADA will however continue to closely monitor research results and developments of these preparations.   To consult the 2011 List, the 2011 Monitoring Programme, a summary of major modifications, explanatory notes on the 2011 List, and a Q&A on major changes, click here.   To consult the 2011 International Standard for Therapeutic Use Exemptions, click here.   Source: WADA Edited World Archery Communication